Skip to main
AQST

AQST Stock Forecast & Price Target

AQST Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aquestive Therapeutics Inc is well-positioned for future financial growth due to its promising pipeline in the no-needle epinephrine market and innovative alternatives for managing severe allergic reactions. Recent FDA announcements regarding the NDA of its product Anaphylm have contributed to a significant surge in share prices, reflecting heightened investor confidence in the company’s regulatory progress and market potential. With ongoing developments in its later-stage pipeline focused on Central Nervous System diseases and a robust commercial portfolio, Aquestive Therapeutics stands to capitalize on unmet medical needs, further enhancing its revenue prospects primarily in the United States.

Bears say

The outlook for Aquestive Therapeutics's stock is negatively influenced by significant risks related to the development of AQST-109, which may not succeed, potentially impacting future revenue projections. There is also a concern regarding a greater-than-expected decline in revenues from existing commercial products, which could undermine financial stability. Additionally, the need for the company to raise capital to bolster its balance sheet raises further red flags regarding its financial health and operational viability.

AQST has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aquestive Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aquestive Therapeutics Inc (AQST) Forecast

Analysts have given AQST a Buy based on their latest research and market trends.

According to 5 analysts, AQST has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aquestive Therapeutics Inc (AQST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.